332 related articles for article (PubMed ID: 15987450)
1. CYP17 5'-UTR MspA1 polymorphism and the risk of premenopausal breast cancer in a German population-based case-control study.
Verla-Tebit E; Wang-Gohrke S; Chang-Claude J
Breast Cancer Res; 2005; 7(4):R455-64. PubMed ID: 15987450
[TBL] [Abstract][Full Text] [Related]
2. The CYP17 MspA1 polymorphism and breast cancer risk: a meta-analysis.
Ye Z; Parry JM
Mutagenesis; 2002 Mar; 17(2):119-26. PubMed ID: 11880540
[TBL] [Abstract][Full Text] [Related]
3. Increased risk of prostate cancer and benign prostatic hyperplasia associated with a CYP17 gene polymorphism with a gene dosage effect.
Habuchi T; Liqing Z; Suzuki T; Sasaki R; Tsuchiya N; Tachiki H; Shimoda N; Satoh S; Sato K; Kakehi Y; Kamoto T; Ogawa O; Kato T
Cancer Res; 2000 Oct; 60(20):5710-3. PubMed ID: 11059764
[TBL] [Abstract][Full Text] [Related]
4. Genetic polymorphism of CYP17 and breast cancer risk in Korean women.
Shin MH; Lee KM; Yang JH; Nam SJ; Kim JW; Yoo KY; Park SK; Noh DY; Ahn SH; Kim B; Kang D
Exp Mol Med; 2005 Feb; 37(1):11-7. PubMed ID: 15761247
[TBL] [Abstract][Full Text] [Related]
5. The relationship between a polymorphism in CYP17 with plasma hormone levels and breast cancer.
Haiman CA; Hankinson SE; Spiegelman D; Colditz GA; Willett WC; Speizer FE; Kelsey KT; Hunter DJ
Cancer Res; 1999 Mar; 59(5):1015-20. PubMed ID: 10070957
[TBL] [Abstract][Full Text] [Related]
6. CYP17 (T-34C) and CYP19 (Trp39Arg) polymorphisms and their cooperative effects on breast cancer susceptibility.
Tüzüner BM; Oztürk T; Kisakesen HI; Ilvan S; Zerrin C; Oztürk O; Isbir T
In Vivo; 2010; 24(1):71-4. PubMed ID: 20133979
[TBL] [Abstract][Full Text] [Related]
7. CYP17 MspA1 polymorphism and risk of biliary tract cancers and gallstones: a population-based study in Shanghai, China.
Hou L; Xu J; Gao YT; Rashid A; Zheng SL; Sakoda LC; Shen MC; Wang BS; Deng J; Han TQ; Zhang BH; Meyers DA; Fraumeni JF; Hsing AW
Int J Cancer; 2006 Jun; 118(11):2847-53. PubMed ID: 16381022
[TBL] [Abstract][Full Text] [Related]
8. Steroid metabolism gene CYP17 polymorphism and the development of breast cancer.
Mitrunen K; Jourenkova N; Kataja V; Eskelinen M; Kosma VM; Benhamou S; Vainio H; Uusitupa M; Hirvonen A
Cancer Epidemiol Biomarkers Prev; 2000 Dec; 9(12):1343-8. PubMed ID: 11142420
[TBL] [Abstract][Full Text] [Related]
9. CYP17 genetic polymorphism, breast cancer, and breast cancer risk factors.
Ambrosone CB; Moysich KB; Furberg H; Freudenheim JL; Bowman ED; Ahmed S; Graham S; Vena JE; Shields PG
Breast Cancer Res; 2003; 5(2):R45-51. PubMed ID: 12631398
[TBL] [Abstract][Full Text] [Related]
10. A polymorphism in the CYP17 gene relates to the risk of recurrent pregnancy loss.
Sata F; Yamada H; Yamada A; Kato EH; Kataoka S; Saijo Y; Kondo T; Tamaki J; Minakami H; Kishi R
Mol Hum Reprod; 2003 Nov; 9(11):725-8. PubMed ID: 14561815
[TBL] [Abstract][Full Text] [Related]
11. Lack of association between CYP17 MspA1 polymorphism and breast cancer risk: a meta-analysis of 22,090 cases and 28,498 controls.
Mao C; Wang XW; He BF; Qiu LX; Liao RY; Luo RC; Chen Q
Breast Cancer Res Treat; 2010 Jul; 122(1):259-65. PubMed ID: 20033766
[TBL] [Abstract][Full Text] [Related]
12. A polymorphism in the CYP17 gene increases the risk of breast cancer.
Feigelson HS; Coetzee GA; Kolonel LN; Ross RK; Henderson BE
Cancer Res; 1997 Mar; 57(6):1063-5. PubMed ID: 9067272
[TBL] [Abstract][Full Text] [Related]
13. Lack of association between CYP17 Mspa1 polymorphism and prostate cancer risk: a meta-analysis of 14494 cases and 15971 controls.
Song G; Gu L; Tian F; Bao Q; Tang Z; Wang S
Medicina (Kaunas); 2013; 49(2):51-5. PubMed ID: 23888338
[TBL] [Abstract][Full Text] [Related]
14. CYP17 gene polymorphism and its association with high-risk north Indian breast cancer patients.
Chakraborty A; Murthy NS; Chintamani C; Bhatnagar D; Mohil RS; Sharma PC; Saxena S
J Hum Genet; 2007; 52(2):159-165. PubMed ID: 17235448
[TBL] [Abstract][Full Text] [Related]
15. CYP17 genotype modifies the association between lignan supply and premenopausal breast cancer risk in humans.
Piller R; Verla-Tebit E; Wang-Gohrke S; Linseisen J; Chang-Claude J
J Nutr; 2006 Jun; 136(6):1596-603. PubMed ID: 16702327
[TBL] [Abstract][Full Text] [Related]
16. Breast cancer risk associated with genotype polymorphism of the estrogen-metabolizing genes CYP17, CYP1A1, and COMT: a multigenic study on cancer susceptibility.
Huang CS; Chern HD; Chang KJ; Cheng CW; Hsu SM; Shen CY
Cancer Res; 1999 Oct; 59(19):4870-5. PubMed ID: 10519398
[TBL] [Abstract][Full Text] [Related]
17. CYP17 genetic polymorphism, breast cancer, and breast cancer risk factors: Australian Breast Cancer Family Study.
Chang JH; Gertig DM; Chen X; Dite GS; Jenkins MA; Milne RL; Southey MC; McCredie MR; Giles GG; Chenevix-Trench G; Hopper JL; Spurdle AB
Breast Cancer Res; 2005; 7(4):R513-21. PubMed ID: 15987458
[TBL] [Abstract][Full Text] [Related]
18. The relationship between a polymorphism in CYP17 with plasma hormone levels and prostate cancer.
Haiman CA; Stampfer MJ; Giovannucci E; Ma J; Decalo NE; Kantoff PW; Hunter DJ
Cancer Epidemiol Biomarkers Prev; 2001 Jul; 10(7):743-8. PubMed ID: 11440959
[TBL] [Abstract][Full Text] [Related]
19. The CYP17 MspA1 polymorphism is not associated with an increased risk of uterine leiomyomas in a Japanese population.
Tsujino T; Ohara N; Yoshida S; Kennedy S; Takemura N; Deguchi M; Maruo T
Gynecol Endocrinol; 2006 Feb; 22(2):87-91. PubMed ID: 16603433
[TBL] [Abstract][Full Text] [Related]
20. Association between the T27C polymorphism in the cytochrome P450 c17alpha (CYP17) gene and risk factors for breast cancer.
Hong CC; Thompson HJ; Jiang C; Hammond GL; Tritchler D; Yaffe M; Boyd NF
Breast Cancer Res Treat; 2004 Dec; 88(3):217-30. PubMed ID: 15609124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
